Washington,
D.C.–Republican
members of the Senate Finance Committee, led by Ranking Member Mike Crapo
(R-Idaho), sent a letter to Senate colleagues emphasizing the wide-ranging
drawbacks of the drug price control mandates contained in the House-passed
Build Back Better Act (BBBA).
The
senators note the tax-and-spending proposal includes a number of problematic
drug pricing provisions that risk undermining biomedical innovation,
exacerbating inflationary pressures, imposing payment cuts on frontline health
care providers, and compromising the United States’ global leadership.
From
the letter:
“Under
the unprecedented and constitutionally dubious system of bureaucratic drug
price controls included in the Build Back Better Act, Americans would see fewer
new treatments and vaccines, greater inflation pressures, and reductions in
health care quality and access for years to come. The bill would
substantially undermine incentives for biomedical innovation, as unaccountable
federal officials would compel a growing number of manufacturers each year to
partake in a mandatory price-setting program, with non-compliance punished by
an impossibly steep penalty of up to 95 percent on gross drug sales across all
markets. Private-sector pricing practices would also come under federal
control, moving us closer to a government-run health care system.
…
“BBBA’s
government drug pricing mandates would also put access to high-quality health
care at risk by burying small businesses in burdensome bureaucratic demands and
instituting aggressive payment cuts for frontline health care providers.
…
“…From
lifesaving treatments to provider access, BBBA represents an unwarranted step
backwards for health care quality and sustainability, and it poses a grave
threat to our global competitiveness. As the Chinese Communist Party and
other rivals abroad look to leverage life sciences innovation to seize market
dominance and strengthen their defense capabilities, our national security and
international leadership demand a more responsible path forward.”
Full
text of the letter, signed by all Republican members of the Finance Committee,
is available here
and below.
______________________
Dear
Colleague,
Over
the course of the past year, Americans have faced a range of pressing
challenges. From skyrocketing inflation and workforce shortages to rising crime
and COVID-19 testing supply strains, this growing list of urgent issues demands
consensus-driven policy solutions. Unfortunately, in spite of these struggles,
the Biden Administration and Congressional Democratic leadership appear to have
chosen to move forward on a reckless tax-and-spending bill that risks
exacerbating the problems at hand and creating new ones.
We
are deeply concerned with the legislation’s proposed price control mandates for
prescription drugs. As a number of independent analyses have indicated, such
bureaucratic government-run price-setting schemes pose a credible threat to the
creation of new medical treatments. They also jeopardize our efforts to combat
inflation, mitigate workforce disruptions, enhance access to care, and maintain
our global competitiveness.
Under
the unprecedented and constitutionally dubious system of bureaucratic drug
price controls included in the Build Back Better Act (BBBA), Americans would
see fewer new treatments and vaccines, greater inflation pressures, and
reductions in health care quality and access for years to come. The bill would
substantially undermine incentives for biomedical innovation, as unaccountable
federal officials would compel a growing number of manufacturers each year to
partake in a mandatory price-setting program, with non-compliance punished by
an impossibly steep penalty of up to 95 percent on gross drug sales across all
markets. Private-sector pricing practices would also come under federal
control, moving us closer to a government-run health care system.
Basic
legal protections and safeguards, meanwhile, would have no place in the BBBA
plan, as the bill expressly and permanently bans judicial and administrative
review of virtually every aspect of the draconian new price control regimes.
According
to researchers from the University of Chicago, these problematic policies would
slash projected biomedical research and development funding by more than $660
billion in the next decades, resulting in 135 fewer new drug approvals and a
potential loss of more than 331 million life years, roughly 31 times the toll
inflicted by the pandemic in the U.S., as of last November. As innovators work
to produce and enhance vaccines and therapies to curb the incidence and effects
of COVID-19, these disincentives for biomedical discovery and development would
prove particularly devastating.
Imagine
the world today without COVID vaccines or treatments, and imagine a world with
a weak or nonexistent pipeline for combating conditions like Alzheimer’s,
sickle cell disease, or cancer. These policy proposals imperil our hopes for
the lifesaving cures and life-enhancing therapies of tomorrow.
BBBA’s
government drug pricing mandates would also put access to high-quality health
care at risk by burying small businesses in burdensome bureaucratic demands and
instituting aggressive payment cuts for frontline health care providers. An
analysis by the nonpartisan American Action Forum found that the Biden
Administration finalized more than $200 billion in new regulatory costs in
2021, imposing a staggering 131.2 million new paperwork hours on job creators.
The tax-and-spending proposal currently under consideration would double down on
this concerning trend toward over-regulation and advance a series of sweeping
new government mandates for stakeholders across the health care system.
For
health care providers, the bill’s price-setting program would have an even more
onerous economic impact, which, according to health care experts at Avalere,
would amount to a roughly 40 percent reduction in add-on payments for the
providers who furnish the medications most likely to be targeted. The doctors’
office setting would see particularly steep cuts, potentially accelerating
health system consolidation and independent practice closures, with stark
access implications for patients across the nation.
In
short, from lifesaving treatments to provider access, BBBA represents an
unwarranted step backwards for health care quality and sustainability, and it
poses a grave threat to our global competitiveness. As the Chinese Communist
Party and other rivals abroad look to leverage life sciences innovation to
seize market dominance and strengthen their defense capabilities, our national
security and international leadership demand a more responsible path forward.
We
stand ready to work with the administration and our colleagues in both chambers
and on both sides of the aisle to develop policies to help address the myriad
challenges facing Americans, including health care access, affordability, and
innovation. We must not, however, enable the unproductive and
innovation-killing government price control mandates included in BBBA to become
law. They would serve only to expand federal control over health care and to
undermine Americans’ ability to compete globally, at the expense of the real
and pressing health care needs facing our country.
Sincerely,